FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

          [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended March 31, 1999

                                       OR

             [   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
       For the transition period from .................to.................

                         Commission file number 33-19583

                            ZEVEX INTERNATIONAL, INC.
               (Exact name of registrant as specified in charter)

          DELAWARE             
                                                          87-0462807       
(State or other jurisdiction                          (I.R.S. Employer
incorporation organization)                            Identification No.)

                4314 ZEVEX Park Lane, Salt Lake City, Utah 84123
              (Address of principal executive offices and zip code)

                                 (801) 264-1001
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
(Former name,former address,and former fiscal year,if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [ X ] No

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate  by check mark  whether  the  registrant  has filed all  documents  and
reports  required  to be filed by  Sections  12,  13 or 15(d) of the  Securities
Exchange Act of 1934 subsequent to the  distribution of securities  under a plan
confirmed by a court.
Yes  [   ]    No  [   ]    Not Applicable  [ X ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest  practicable date. As of May 3, 1999, the Company
had issued 3,418,876 shares of common stock, par value $0.001 per share.

<PAGE>


PART I

                              FINANCIAL INFORMATION

-------------------------------------------------------------------------------

               ITEM 1. FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q
-------------------------------------------------------------------------------

ZEVEX International,  Inc. (the "Company"), files herewith balance sheets of the
Company as of March 31, 1999, and December 31, 1998, and the related  statements
of operations and cash flows for the respective  three month periods ended March
31, 1999 and 1998.  In the opinion of the  Company's  management,  the financial
statements   reflect  all  adjustments,   all  of  which  are  normal  recurring
adjustments,  necessary to fairly present the financial condition of the Company
for the interim periods  presented.  The financial  statements  included in this
report on Form 10-Q should be read in  conjunction  with the  audited  financial
statements of the Company and the notes thereto included in the annual report of
the Company on Form 10-K for the year ended December 31, 1998.


<PAGE>


                            ZEVEX INTERNATIONAL, INC.
                           CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
<S>                                                  <C>                  <C>                            <C>    
                                                                            Mar. 31                       Dec. 31

                                                                             1999                          1998
                                                                             -----                         ----
                                                                          (unaudited)
                                                       ASSETS
Current assets:
              Cash and cash equivalents                                     $ 4,352,882                   $ 7,960,511
              Restricted cash for sinking
                 Fund payment on IDB                                            209,141                       182,049
              Accounts receivable                                             4,243,771                     3,435,181
              Inventories                                                     5,792,182                     5,574,394
              Marketable securities                                             607,017                     1,598,032
              Deferred income taxes                                             200,643                       249,251
              Prepaid expenses                                                                         
                                                                         ------------
                                                                                 80,128                        65,561
                                                                                 ------                        ------
                              Total current assets                           15,485,764                    19,064,979

              Property and equipment, net                                     5,518,217                     5,505,643
              Patents and trademarks, net                                       137,856                       139,792
              Goodwill, net                                                   8,850,675                     8,998,006
              Other assets                                                       40,321                        52,559
                                                                                 ------                        ------
                                                                           $ 30,032,833                  $ 33,760,979
                                                                           ============                  ============

                                         LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
              Accounts payable                                              $ 1,133,156                   $ 1,076,110
              Other accrued expenses                                            683,081                       469,079
              Income taxes payable                                              100,592                        50,891
              Other current liabilities                                          59,194                       215,873
              Bank lines of credit                                              492,839                       541,993
              Current portion of long-term debt                                 804,217                     5,042,000
                                                                               -------                      ---------
                              Total current liabilities                       3,273,079                     7,395,946

             Deferred income taxes                                             130,015                         97,228
             Industrial development bond                                     1,800,000                      1,800,000
             Convertible debt, long-term                                     4,350,000                      4,350,000
             Other long-term liabilities                                            --                          3,270

Stockholders' equity:
              Common stock, $.001 par value: authorized
              10,000,000  shares, issued 3,418,876
                   respectively for 1999 and 1998                                 3,419                         3,419
              Additional paid in capital                                     17,381,793                    17,381,793
              Less: Treasury stock                                             (50,790)                      (50,790)
              Unrealized loss on  marketable securities, net                   (69,873)                     (147,309)
              Retained earnings                                               3,215,190                     2,927,422
                                                                              ---------                     ---------
                           Total stockholders' equity                        20,479,739                    20,114,535
                                                                             ----------                    ----------
                                                                           $ 30,032,833                  $ 33,760,979
                                                                           ============                  ============
</TABLE>


See accompanying notes.


<PAGE>



                            ZEVEX INTERNATIONAL, INC.
                            STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
<S>                                    <C>       <C>           <C>    

                                                 Three months ended
                                                      March 31,
                                              1999                 1998
                                        -----------------     ----------------
                                          (unaudited)           (unaudited)
Revenue:
   Product sales                            $  4,298,226         $  2,138,551
   Engineering services                          363,227               49,160
                                        -----------------     ----------------
                                               4,661,453            2,187,711
Cost of sales                                  2,387,107            1,277,423
                                        -----------------     ----------------
Gross profit                                   2,274,346              910,288

Operating expenses:
   General and administrative                  1,050,827              532,327
   Selling and marketing                         529,443              298,217
   Goodwill amortization                         147,331                   --
   Research and development                      129,062              104,084
                                        -----------------     ----------------

Total operating expenses                       1,856,663              934,628

Operating income (loss)                          417,683             (24,340)
Other income (expense):
   Interest income                                54,769              113,214
   Interest expense                            (105,030)             (16,767)
   Unrealized gain on
     marketable securities                        87,903               62,496
                                        -----------------     ----------------
Income before provision for
   income taxes                                  455,325              134,603

Provision for income taxes                     (167,557)             (19,595)
                                        -----------------     ----------------

Net income                              $        287,768      $       115,008
                                        =================     ================

Basic net income per share              $            .08      $           .04
                                        =================     ================
Weighted average shares
   outstanding                                 3,412,176            3,280,843
                                        =================     ================
Diluted net income per share
                                                     .08                  .03
                                        =================     ================
Diluted weighted average shares
   outstanding                                 3,624,475            3,659,104
                                        =================     ================
</TABLE>


See accompanying notes.
<PAGE>


                            ZEVEX INTERNATIONAL, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
<S>                                                               <C>    <C>           <C>    



                                                                          Three months ended
                                                                               March 31,
                                                                        1999                1998
                                                                   ---------------     ---------------
                                                                    (unaudited)         (unaudited)
Cash flows from operating activities

Net income                                                             $  287,768          $  115,008

Adjustments  to  reconcile  net  income  to net cash  provided  by (used  in) by
operating activities:
      Depreciation and amortization                                       328,567              69,000
      Deferred income taxes                                                81,395              19,595
      Decrease (increase) on marketable securities                      1,068,451            (92,463)
      Changes in operating assets and liabilities:
         Increase in restricted cash for sinking fund payment
            on industrial development bond                               (27,092)            (25,970)
         (Increase) decrease in accounts receivable                     (808,590)              93,986
         Increase in inventories                                        (217,788)           (121,769)
         (Increase) decrease in prepaid expenses                         (14,567)              30,396
         Decrease in other assets                                          12,238                  --
         Increase in accounts payable                                      57,046             105,481
         Increase in accrued liabilities                                   20,770               1,567
         Increase (decrease) in income taxes payable                       49,701           (244,656)
                                                                   ---------------     ---------------
Net cash provide by (used in) operating activities                        837,899            (49,825)
Cash flows from investing activities
Purchase of property and equipment                                      (191,214)           (787,740)
Additions of patents and trademarks                                         (660)                  --
                                                                   ---------------     ---------------
Net cash used in investing activities                                   (191,874)           (787,740)
Cash flows from financing activities
Payments on debt related to business acquisitions                     (4,204,500)                  --
Proceeds from bank line of credit                                         492,839                  --
Repayment of bank line of credit                                        (541,993)                  --
Proceeds from exercise of stock options                                        --               4,625
Proceeds from exercise of warrants                                             --             105,000
Purchase of treasury stock                                                     --            (50,790)
                                                                   ---------------     ---------------
Net cash (used in) provided by financing activities                   (4,445,528)              58,835
                                                                   ---------------     ---------------
Net (decrease) in cash and cash equivalents                           (3,607,629)           (778,730)
Cash and cash equivalents at beginning of period                        7,960,511           2,260,426
                                                                   ---------------     ---------------
Cash and cash equivalents at end of period                            $ 4,352,882         $ 1,481,696
                                                                   ===============     ===============


</TABLE>

See accompanying notes.
<PAGE>


                            ZEVEX INTERNATIONAL, INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                 March 31, 1999


1.  Summary of Significant Accounting Policies

Description of Organization and Business

The Company was  incorporated  under the laws of the State of Nevada on December
30, 1987. The Company was originally incorporated as Downey Industries, Inc. and
changed it's name to ZEVEX  International,  Inc. on August 15, 1988. In November
1997 the Company  reincorporated  into  Delaware.  During  1998,  the  Company's
operations consisted of the business of its wholly-owned subsidiary, ZEVEX, Inc.
In December 1998, the Company acquired an additional  product line and completed
the  acquisition of two additional  subsidiaries,  Aborn  Electronics,  Inc. and
JTech  Medical  Industries,  Inc.  The Company and its  subsidiaries  design and
manufacture  advanced  medical  devices,   including  surgical  systems,  device
components,  and sensors for medical and industrial  technology  companies.  The
Company and its  subsidiaries  also  design,  manufacture,  and market their own
medical  devices  using  proprietary  technologies.  The  Company's  design  and
manufacturing  service  customers are primarily  medical  technology  companies,
which sell the Company's systems and devices under private labels or incorporate
the Company's devices into their products.

Principles of Consolidation

The consolidated  balance sheet at March 31, 1999 and December 31, 1998 includes
the  accounts  of  ZEVEX  International,  Inc.  (Company)  and its  wholly-owned
operating subsidiaries,  ZEVEX, Inc., Aborn Electronics, Inc., and JTech Medical
Industries,  Inc. The consolidated  statement of operations excludes the results
of Aborn  and JTech for March 31,  1998,  because  these two  acquisitions  were
consummated  effective  as  of  December  31,  1998.  At  March  31,  1998,  the
consolidated  financial  statements include the accounts of ZEVEX International,
Inc.  (Company)  and its  wholly-owned  operating  subsidiary  ZEVEX,  Inc.  All
significant  intercompany  balances and  transactions  have been  eliminated  in
consolidation.

Basis of Presentation

The  accompanying  financial  statements  have been prepared in accordance  with
generally accepted accounting  principles for interim financial  information and
with the  instructions  to Form 10-Q of  Regulation  S-X.  Accordingly,  certain
information and footnote  disclosures  normally  included in complete  financial
statements have been condensed or omitted.  These financial statements should be
read in conjunction with the financial statements and footnotes thereto included
in the Company's 1998 Annual Report on SEC Form 10-K.

In the  opinion  of  management,  all  adjustments  (consisting  of  normal  and
recurring  adjustments)  considered  necessary for a fair presentation have been
included.  The results of operations  for interim  periods are not indicative of
the results of operations to be expected for a full year.


2.  Bank Line of Credit

The Company renewed its line of credit arrangement with a financial  institution
for $5  million.  The  line  matures  on May 31,  1999.  The line of  credit  is
collateralized  by accounts  receivable  and inventory and bears interest at the
prime rate, 7.75% at March 31, 1999 and December 31, 1998. The Company's balance
on its line of credit was  $492,839 at March 31,  1999 and  $441,993 at December
31, 1998.  Under the line of credit  agreement,  the Company is restricted  from
declaring cash  dividends.  In addition,  the Company's line of credit  contains
certain financial covenants. As of March 31, 1999, the Company was in compliance
with these financial covenants.

In  addition,  JTech  had a line of  credit  with a  financial  institution  for
$150,000.  The line bore  interest at the prime rate plus 1% (8.75% at March 31,
1999 and  December 31, 1998) that matured on March 15, 1999 and was not renewed.
The balance  under this line of credit was $100,000 at December  31,  1998.  The
line of credit was  collateralized  by all of the assets of JTech and  contained
certain  covenants.  JTech was in compliance with the debt covenants at December
31, 1998.


3.  Repurchase of Common Stock

On February 4, 1998, the Company  repurchased 6,700 shares of outstanding Common
Stock  for  $50,790.  The  Company  anticipates  that  all  the  shares  will be
contributed to the Employees' Stock Ownership Plan.


4.  Related Party Transactions

On December 31, 1998,  the Company  acquired  JTech pursuant to a Stock Purchase
Agreement among the Company and the four shareholders of JTech (the "JTech Stock
Purchase").  Leonard C. Smith, one of the selling JTech  shareholders,  received
$1,257,900  in cash and a  convertible  debenture in  connection  with the JTech
Stock  Purchase.  The  convertible   debenture,   in  the  principal  amount  of
$1,290,000,  is due January 6, 2002 and is  convertible  at Mr.  Smith's  option
during the period from January 6, 2000 to January 6, 2002 at $11 per share.

JTech also entered into an  Employment  Agreement  with Leonard C. Smith,  dated
December 31, 1998, which provides that Mr. Smith serve as President of JTech for
three  years at a salary  of  $100,000  per  year.  Pursuant  to the  employment
agreement,  Mr. Smith also  received an option to purchase  40,000 shares of the
Company's  common  stock,  vesting  over four  years,  at $4.875 per share,  the
closing  price of such stock on Nasdaq on the date of the JTech Stock  Purchase.
Mr. Smith was appointed to fill a vacancy on the  Company's  Board of Directors,
effective  April 26, 1999. Mr. Smith's term on the Board will expire at the 2001
annual meeting of shareholders.

On April 15, 1997, the Company entered into a consulting  agreement with another
company owned by certain  stockholders to provide  services related to strategic
planning, public relations,  financing and potential acquisition of new products
or companies. Under the consulting agreement, the Company paid an initial fee of
$50,000,  and pay $10,000 per month for two years.  In addition,  these  certain
stockholders  have the right to nominate one director to the Company's  Board of
Directors.  The certain stockholders exercised this right with its nomination of
Kirk  Blosch in June 1998.  Mr.  Blosch is serving a 3-year  term as a director,
which term  expires at the annual  meeting  of  shareholders  in June 1999.  Mr.
Blosch has been nominated to serve another 3-year term.

In connection  with the secondary  public  offering  completed in November 1997,
certain  stockholders waived their registration  rights on 350,000 warrants.  In
exchange,  the Company and these  stockholders  executed a  registration  rights
agreement,  entitling these stockholders to certain demand  registration  rights
for a period of two years from February 1, 1998.


5.       Comprehensive Income

Effective January 1, 1998, the Company adopted Statement of Financial Accounting
Standards  ("SFAS")  No. 130,  "Reporting  Comprehensive  Income".  SFAS No. 130
requires that all items recognized  under accounting  standards as components of
comprehensive  income be  reported  in an  annual  financial  statement  that is
displayed with the same prominence as other annual  financial  statements.  This
statement  also requires that an entity  classify  items of other  comprehensive
income by their nature in an annual  financial  statement.  Other  comprehensive
income may include  foreign  currency  translation  adjustments,  and unrealized
gains and losses on marketable securities classified as available-for-sale.  For
the three months  ending March 31,  1999,  SFAS No. 130 would have  required the
Company to show comprehensive  income of $77,346 (net of tax effect) higher than
net income reported on the Company's financial statements.


<PAGE>


-------------------------------------------------------------------------------

                 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
-------------------------------------------------------------------------------

Results of Operations

The Company's  revenues for the first quarter of 1999  increased to  $4,661,453,
from $2,187,711 for the first quarter of 1998, an increase of approximately 113%
for the three months  ending  March 31,  1999.  During the first three months of
1999, 14% of total revenues  resulted from sales to one customer,  who was not a
major  customer in 1998,  compared to 48% of total  revenues for the first three
months  of  1998,  from  sales  to  three  customers.  Sales  of  the  Company's
proprietary enteral feeding products line accounted for approximately 34% of the
total  revenues  for the first  quarter of 1999,  compared  to 21% for the first
quarter  of  1998.  Sales  of the  Company's  proprietary  JTech  product  line,
accounted for  approximately  20% of the total revenues for the first quarter of
1999. Forty-six percent of the Company's revenues in the first quarter 1999 were
products,  which are manufactured for and sold to OEM customers,  who market the
final product. The Company's contract  manufacturing revenue growth depends upon
growth in demand for systems, devices and instruments manufactured by ZEVEX, and
ZEVEX's  ability to acquire  additional  manufacturing  service  contracts  from
medical  technology  companies.  ZEVEX's contract  manufacturing  customers have
complete   control  over  the   marketing  and  sales  of  products  that  ZEVEX
manufactures  for them.  ZEVEX has no ability to increase demand for instruments
that it manufactures for its contract-manufacturing customers. No assurances can
be given that orders from any customer will increase or remain at current levels
or that they will not decline.

The Company's gross profit as a percentage of revenues was approximately 49% for
the first  quarter of 1999,  as compared  to 42% for the first  quarter of 1998.
Management attributes the increase mainly to an increase in revenues relating to
the Company's proprietary products.

Selling,  general and  administrative  expenses for the quarter  ended March 31,
1999,  increased  $749,726,  from  $830,544  in the  first  quarter  of  1998 to
$1,580,270  in the first  quarter  1999.  Increased  expenses  resulted from the
Company's  continuing growth, which has resulted primarily from the acquisitions
of JTech and Aborn.  An  expanded  sales and  marketing  effort  also  increased
staffing, travel, advertising and administrative expenses related to the enteral
feeding and JTech  product  lines.  The Company also had an increase in expenses
related to  employees,  such as  insurance,  taxes,  and pension  benefits.  The
Company believes that general and administrative  expenses in 1999 will continue
at approximately the same percentage of sales as in the previous two years.

Research and development  expenses vary from quarter to quarter depending on the
number and nature of pending research and development projects and their various
stages of completion. During the first quarter of 1999, research and development
expenses were $129,062,  compared to $104,084  during the first quarter of 1998.
Expenses incurred during the first quarter were for the continued development of
new applications of the Company's ultrasound technology and proprietary products
for both  ZEVEX  and  JTech.  Management  believes  investing  in  research  and
development  will serve the Company's  future well, and intends to continue this
kind of investment for the  foreseeable  future with expected  expenditures  for
1999 at approximately $600,000.

Net income increased to $287,768,  approximately 6.2% of revenues,  in the first
quarter of 1999,  from $115,008,  approximately  5.3% of revenues,  in the first
quarter of 1998. The increase in net income during the first quarter of 1999, as
compared to the first quarter of 1998, is principally due to increased  revenues
and the  decreased  cost of sales  mentioned  above,  related to the  additional
revenues of the proprietary products.

As of March 31,  1999,  the  Company's  backlog  of OEM  contract  manufacturing
customer  orders was  $5,593,245,  as compared to  $7,001,866 on March 31, 1998.
Management  estimates  that  approximately  80% of the backlog  will ship before
December 31, 1998.


Liquidity and Capital Resources

During the quarter  ending  March 31,  1999,  the  Company had  $837,899 of cash
provided by operating activities,  compared to $49,825 of cash used in operating
activities in the first quarter of 1998.  Cash  decreased by $3,607,629  for the
three months ending March 31, 1999, as the Company made payments on debt related
to the  business  acquisitions  of JTech and Aborn,  and  continuing  to fund an
increase in accounts receivable and inventories,  and purchases related to plant
and equipment

The Company's investment in property, new research,  production,  test equipment
and tooling was $191,214 for the first quarter of 1999,  compared to $787,740 in
1998. The Company paid $580,000 in the exercise of its first right of refusal to
purchase  a parcel  of  land,  approximately  3.47  acres,  to the  north of its
facility in the first quarter of 1998.  Total  expenditures for equipment in the
first  quarter of 1999 was  $191,214,  primarily  for  upgrading  the  Company's
research,  design,  manufacturing,  and  engineering  capabilities.  The Company
expects to spend approximately $240,000 for the remainder of 1999 for additional
manufacturing  equipment and software,  as well as for normal replacement of old
equipment.  The Company  also  anticipates  spending  approximately  $600,000 in
additional research and development expenses during 1999.

The Company's  working  capital at March 31, 1999 was  $12,112,685,  compared to
$16,716,466 at March 31, 1998. The decrease in working  capital is primarily due
to the payments on debt related to the acquisitions  completed in December 1998,
as described in the Acquisition  section of the Notes to Consolidated  Financial
Statements  in the  Company's  Annual  Report on SEC Form 10-K.  The  portion of
working capital represented by cash at such dates was $4,352,882 and $1,481,696,
respectively.  The Company  uses  substantial  portions of its cash from time to
time to fund  its  operations,  including  increases  in  inventories,  accounts
receivable and work in process in connection with various  customer  orders,  as
well as acquisitions of additional technologies and product complementary to the
Company's  current  technologies  and  products.  The Company  feels its working
capital is sufficient for operations for the next twelve months.



<PAGE>


Cautionary Statement for Purposes of "Safe Harbor Provisions" of the Private 
Securities Litigation Reform Act of 1995

When used in this report, the words "estimate," "believe," "project" and similar
expressions,  together with other  discussion  of future trends or results,  are
intended to identify  forward-looking  statements  within the meaning of Section
27A of the Securities Act of 1933, as amended (the "Securities Act") and Section
21E of the  Securities  Exchange Act of 1934, as amended (the  "Exchange  Act").
Such statements are subject to certain risks and uncertainties,  including those
discussed below, that could cause actual results to differ materially from those
projected.  These  forward-looking  statements speak only as of the date hereof.
All of these  forward-looking  statements are based on estimates and assumptions
made by management of the Company, which although believed to be reasonable, are
inherently uncertain and difficult to predict.  Therefore, undue reliance should
not be placed upon such  estimates.  There can be no assurance that the benefits
anticipated in these forward-looking  statements will be achieved. The following
important  factors,  among  others,  could  cause the Company not to achieve the
benefits  contemplated  herein,  or  otherwise  cause the  Company's  results of
operations  to be  adversely  affected  in  future  periods:  (i)  continued  or
increased competitive pressures from existing competitors and new entrants; (ii)
unanticipated  costs related to the Company's  growth and operating  strategies;
(iii) loss or retirement of key members of management; (iv) increase in interest
rates of the Company's  cost of borrowing,  or a default under any material debt
agreement;  (vi) prolonged labor disruption;  (viii) deterioration in general of
regional  economic  conditions;  (ix) adverse  state or federal  legislation  or
regulation  that  increases  the cost of  compliance,  or adverse  findings by a
regulator  with  respect  to  existing  operations;  (x) loss of  customers;(xi)
adverse  determinations in connection with pending or future litigation or other
material  claims and judgments  against the Company;  (xii) inability to achieve
future sales; and (xiii) the  unavailability of funds for capital  expenditures.
Many of such factors are beyond the control of the Company.  Please refer to the
Company's  SEC Form 10-K for its  fiscal  year  ended  December  31,  1998,  for
additional cautionary statements.


<PAGE>


                                     PART II
                  OTHER INFORMATION NOT APPLICABLE AT THIS TIME

Item 1.  Legal Proceedings
Item 2.  Changes in Securities and Use of Proceeds
Item 3.  Defaults upon Senior Securities
Item 4.  Submission of Matters to a Vote of Security Holders
Item 5.  Other Information
Item 6.  Exhibits and Reports on Form 8-K



-------------------------------------------------------------------------------

                                   SIGNATURES
-------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


ZEVEX INTERNATIONAL, INC.


Dated:  May 13, 1999
                                     By   /s/ Dean G. Constantine   
                                       Dean G. Constantine, President


                                      By   /s/ Phillip L. McStotts    
                                        Phillip L. McStotts, Secretary
                                         (Principal Financial Officer)